Cough variant and cough-predominant asthma are major causes of persistent cough: a multicenter study in Japan

Niimi, Akio; Ohbayashi, Hiroyuki; Sagara, Hironori; Yamauchi, Kohei; Akiyama, Kazuo; Takahashi, Kiyoshi; Inoue, Hideki; Wakayama, Tomoshige; Kobayashi, Hitoshi; Hasegawa, Masato; Kimura, Goro; Yokoe, Takuya; Adachi, Mitsuru

doi:10.3109/02770903.2013.823444

Cited by 50 publications

(26 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The proportions of clinical diagnosis of causative diseases for cough in our study are different from the previous study that investigated the epidemiology of persistent cough in Japan . This might be caused by the difference of the inclusion criteria between the previous and the present study.…”

Section: Discussioncontrasting

confidence: 90%

See 1 more Smart Citation

Measurement of eNO with portable analyser might improve the management of persistent cough at primary care practice in Japan

Watanabe

Shinkai

Shinoda

et al. 2014

Clinical Respiratory J

View full text Add to dashboard Cite

show abstract

Section: Discussioncontrasting

confidence: 90%

“…We excluded the patients with persistent cough whose pulmonary auscultation was not normal. On the other hand, the previous study included the persistent cough patients with wheeze . These made the different epidemiology of the causes of cough.…”

Section: Discussionmentioning

confidence: 99%

Measurement of eNO with portable analyser might improve the management of persistent cough at primary care practice in Japan

Watanabe

Shinkai

Shinoda

et al. 2014

Clinical Respiratory J

View full text Add to dashboard Cite

show abstract

“…But in some situations, drug particles from inhalers may induce cough, due to irritability of airways. We previously reported that TP had effectiveness among patients with cough‐predominant asthma, as well as cough‐variant asthma, in a multicentre epidemiological study . TP may have superiority with its transdermal therapeutic system in the treatment of cough.…”

Section: Discussionmentioning

confidence: 98%

A 12‐week, randomized, parallel‐group, proof‐of‐concept study of tulobuterol patch and salmeterol inhaler as add‐on therapy in adult‐onset mild‐to‐moderate asthma

Inoue

Matsumoto

Ito

et al. 2016

Clin Exp Pharma Physio

Self Cite

View full text Add to dashboard Cite

Patch formulation of tulobuterol has been used in asthma treatment as a long-acting β -agonist (LABA) through sustained skin absorption. Its treatment efficacy, especially in small airways, remains poorly understood. The study aim was to investigate LABA add-on effects of tulobuterol patch (TP) and salmeterol inhaler (SA) on pulmonary function, asthma control and health status. Patients who had adult-onset under-control asthma, despite taking inhaled corticosteroids, were enrolled in a randomized, open-label, parallel-group, proof-of-concept study of 12-week add-on treatment with TP (n=16) or SA (n=17). Spirometry, impulse oscillometry (IOS), exhaled nitric oxide levels, and clinical questionnaires of asthma control, health status (St. George's Respiratory Questionnaire: SGRQ), and symptoms were evaluated every 4 weeks. Add-on treatment of SA significantly improved the spirometric indices of small airway obstruction (forced expiratory flow between 25% and 75% of FVC: FEF , and maximum expiratory flow at 25% of FVC: MEF ) and IOS indices of whole respiratory resistance (resistance at 5 Hz) as compared to TP. In intra-group comparisons, add-on treatment of TP improved the scores of the asthma control test and the total SGRQ, as well as the symptom and impact components of the SGRQ. SA add-on treatment improved FEV and IOS parameters of resistance at 20 Hz and reactance at 5 Hz. Neither of the treatments improved exhaled nitric oxide levels. In conclusion, add-on treatment of TP improved asthma control and health status, whereas SA improved pulmonary function measures associated with large and small airway involvement among patients with adult-onset mild-to-moderate asthma.

show abstract

“…Cough variant asthma (CVA) is the most common cause of prolonged/chronic cough (42.2%), followed by cough-predominant asthma (28.4%), in Japan [4]. In classic asthma, variable airflow obstruction typically leads to symptoms such as wheeze, dyspnea, and cough.…”

Section: Introductionmentioning

confidence: 99%

Cough variant asthma patients are more depressed and anxious than classic asthma patients

Saito

Itoga

Tamaki

et al. 2015

Journal of Psychosomatic Research

View full text Add to dashboard Cite

Cough variant and cough-predominant asthma are major causes of persistent cough: a multicenter study in Japan

Abstract: These findings show that CVA and CPA are the main causes of cough persisting for ≥3 weeks.

Cited by 50 publications

References 32 publications

Measurement of eNO with portable analyser might improve the management of persistent cough at primary care practice in Japan

Measurement of eNO with portable analyser might improve the management of persistent cough at primary care practice in Japan

A 12‐week, randomized, parallel‐group, proof‐of‐concept study of tulobuterol patch and salmeterol inhaler as add‐on therapy in adult‐onset mild‐to‐moderate asthma

Cough variant asthma patients are more depressed and anxious than classic asthma patients

Contact Info

Product

Resources

About